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Abstract 
Background 
As pathogenic variants in the gene for RBM20 appear with a frequency of 6 % among Danish 
patients with dilated cardiomyopathy (DCM), it was the aim to investigate the associated 
disease expression in affected families. 
 
Methods and Results 
Clinical investigations were routinely performed in DCM index-patients and their relatives. 
In addition, ≥76 recognized and likely DCM-genes were investigated. DNA-sequence-
variants within RBM20 were considered suitable for genetic testing when they fulfilled the 
criteria of (a) being pathogenic according to the ACMG-classification, (b) appeared with an 
allele frequency of <1:10.000 and (c) segregated with DCM in ≥7 affected individuals.  
 
A total of 80 individuals from 15 families carried five different pathogenic RBM20-variants 
considered suitable for genetic testing. The penetrance was 66% (53/80) and age-dependent. 
Males were both significantly younger and had lower ejection fraction at diagnosis than 
females (age: 29±11 versus 48±12 years; p<0.01. Ejection fraction: 29±13 versus 38±9%; 
p<0.01). Furthermore, 11 of 31 affected males needed a cardiac transplant while none of 22 
affected females required this treatment (p<0.001). Thirty percent of RBM20-carriers with 
DCM died suddenly or experienced severe ventricular arrhythmias while no adverse events 
were identified among healthy RBM20-carriers with a normal cardiac investigation. The 
event-free survival of male RBM20-carriers was significantly shorter compared to female 
carriers (p<0.001).  
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Conclusions 
The disease expression associated with pathogenic RBM20-variants was severe especially in 
males. The findings of the current study suggested that close clinical follow-up of RBM20-
carriers is important which may ensure early detection of disease development and thereby 
improve management. 
 
Keywords 
Dilated cardiomyopathy; Sudden cardiac death; Genotype-phenotype correlations; RBM20-
variants. 
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Clinical Perspectives 
 
What is new 
• This study represents the most comprehensive investigation to date of the disease 
expression in 80 carriers of pathogenic DNA-sequence variants in the gene for 
RBM20 
• Sixty percent of all male RBM20-carriers experienced a major cardiovascular event 
before the age of 40 years while this happened in less than 5% of females 
• Only male carriers developed end-stage heart failure requiring cardiac transplantation  
• Pathogenic RBM20-variants were associated with a severe disease expression which 
appeared to be sex specific since males had a significantly shorter event-free survival 
rate than female carriers 
 
  
Clinical Implications 
• The severe disease expression in carriers of pathogenic RBM20-variants, suggested 
that close clinical follow-up of affected as well as unaffected individuals is warranted 
to ensure adequate and timely treatment 
• Primary prophylactic ICD-treatment may be considered in carriers of pathogenic 
RBM20-variants once they develop DCM, since one third of the affected individuals 
either died suddenly or experienced episodes of ventricular fibrillation/sustained 
ventricular tachycardia 
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Introduction 
Dilated cardiomyopathy (DCM) is a condition characterized by unexplained dilation and 
impaired systolic function of the left ventricle (LV).1 The most common presentation is with 
symptoms of heart failure (HF), while ventricular arrhythmias and sudden cardiac death 
(SCD) are less frequent as the initial manifestation of the disease.1 The prognosis has 
improved considerably over the past decades due to better medical treatment, use of cardiac 
resynchronization therapy and application of implantable cardiac defibrillators (ICD).2 
However, DCM remains to be one of the most frequent causes of end-stage HF and heart 
transplantation (HTx).3  
 
The disorder has an estimated prevalence of 1:2500 and a familial appearance (>1 affected 
individual) in 30-50% of cases.4-6 In the context of familial disease DCM is most often 
transmitted by autosomal dominant inheritance and genetic investigations have reported 
pathogenic sequence variants in more than 100 different genes.7 So far, disease-associated 
DNA-sequence-variants have most frequently been identified in the giant gene for Titin 
(TTN) encoding part of the cytoskeleton, sarcomeric protein genes and the gene for lamin 
A/C which encodes a protein of the nuclear envelope.7 
 
Recently, the gene for ribonucleic acid binding protein motif 20 (RBM20) was reported as the 
first DCM gene with regulatory properties that influences the posttranslational splicing of 
variety of genes including TTN.8 
 
So far, only few studies of RBM20 have reported about the relationship between genotype 
and phenotype.8-12 The clinical information from these investigations has been limited by 
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small numbers of individual patients (index-patients) or families with few affected relatives 
and a short period of follow-up. It was the aim of the study to substantiate our knowledge 
about the disease expression associated with pathogenic DNA-sequence-variants in RBM20 
by clinical investigations of a significant number of affected individuals followed for a 
considerable period of time.  
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Methods 
The data, analytic methods, and study materials will be made available on reasonable request 
to other researchers for purposes of reproducing the results or replicating the procedures. 
 
Study Cohort 
This investigation complied with the Declaration of Helsinki. It was approved by the local 
ethics committee (S-20140073) and the Danish data protection agency (14/17347). Informed 
consent was obtained from all participants. 
 
Patients and relatives were included in the period from 2011 to 2017 at three tertiary referral 
University Hospitals of which one was also a transplant center. The catchment area of the 
hospitals included the geographical areas of Funen and Jutland which represented 54% 
(3.122.253/5.778.570 individuals) of the Danish population in 2017.13 The study cohort 
consisted of unrelated index-patients with Caucasian ethnicity and a diagnosis of DCM who 
were shown to carry pathogenic DNA-sequence-variants in the gene for RBM20 following 
genetic investigations. Clinical data of the patients were collected retrospectively from their 
initial diagnosis of DCM until inclusion in the study and from then, prospectively until their 
most recent follow-up, their time of death or HTx. 
In addition, their relatives at risk of disease development, who accepted the offer of 
predictive genetic testing and were shown to carry the pathogenic DNA-sequence-variant 
within RBM20 of the index-patient, were also included in the study.  
Information about family members who died before the current investigation was obtained 
retrospectively by reviewing available hospital notes and autopsy reports.  
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Information from each individual participating in the study was collected at multiple time 
points and included: (1) symptoms of cardiac disease, (2) results of ECG- and Holter-
recordings, (3) results of echocardiography, (4) implantation of pacemaker or defibrillator (5) 
disease complications including ventricular arrhythmias, HTx, and (6) all-cause mortality. 
 
Control Cohort 
The control cohort consisted of patients with familial DCM defined as the presence of >1 
affected individual following clinical investigations of relatives at risk of having inherited the 
condition. Furthermore, genetic investigations of ≥76 recognized and likely DCM-genes (see 
below) had been unable to identify any pathogenic or likely pathogenic DNA-sequence-
variants. This cohort of patients fulfilled the same diagnostic criteria as the study cohort and 
was included at the same time and location as carriers of pathogenic RBM20-variants. 
 
Echocardiography and Diagnostic Criteria 
All individuals in the study- and control- cohort underwent echocardiography included 
standard two-dimensional measurements of left ventricular end-diastolic diameter (LVEDd) 
and left ventricular ejection fraction (LVEF) by Simpson’s bi-plane method. Dimensions 
were corrected for age and body surface area (BSA) according to the formula of Henry 
[(LVEDd)(percent predicted) = measured LVEDd/predicted LVEDd X 100; predicted 
LVEDd = [45.3 X BSA0.3] - [0.03 X age]  - 7.2.14  
 
DCM was diagnosed in accordance with generally accepted criteria when echocardiography 
identified unexplained left ventricle dilation and impaired contractile performance with a 
LVEDd >112% predicted for age and BSA and a LVEF ≤45%.1  
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Coronary disease was excluded in index-patients >35 years of age at diagnosis by the use of 
coronary angiography or cardiac computed tomography.15 In addition, patients who were 
pregnant or had hypertension, a history of alcohol abuse, heart valve disease, congenital heart 
disease, autoimmune, endocrine, metabolic or neuromuscular disease known to be associated 
with HF were not included in the study. 
RBM20-carriers who experienced SCD <50 years of age were also considered to have 
DCM.15 
 
Sudden Cardiac Death (SCD) 
SCD was defined in accordance with generally accepted criteria as a sudden and natural 
unexpected death. In un-witnessed cases SCD was defined as the cause of death in a person 
last seen alive and functioning normally 24 hours before dying and in witnessed cases as an 
acute change in cardiovascular status within one hour of the time to death.16 
 
Ventricular Arrhythmia (VA) 
VA was defined as documented episodes of (a) sustained ventricular tachycardia (VT) lasting 
>30 seconds requiring cardioversion, (b) ventricular fibrillation (VF) or (c) SCD. 
 
Genetic Investigations 
All index-patients in both the study and control cohort underwent genetic investigations by 
use of Illumina Hiseq NGS technology. Three different laboratories were used which all 
fulfilled the requirements for clinical diagnostic testing according to the UNE-EN ISO 15189 
quality standard.17-19 The number of genes investigated varied from 76 to 242 and depended 
solely on the diagnostic gene panels provided by the individual laboratory (Table 1S).  
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Once a pathogenic DNA-sequence-variant was identified in the index-patient, relatives were 
offered predictive testing by use of Sanger Sequencing of the specific variant. 
 
Filtering and Classification of DNA-Sequence-Variants 
Sequence variants were filtered and classified according to the consensus recommendations 
from the American College of Medical Genetics and Genomics and the Association for 
Molecular Pathology (ACMG) as pathogenic (P), likely pathogenic (LP), variant of unknown 
significance (VUS), benign or likely benign.20 The initial raw filtering and classification was 
obtained by use of the software Ingenuity Variant Analysis (IVA, Qiagen®) and Intervar 
(Wang Genomics Lab®).21-23 Subsequently, all P/LP variants as well as VUS were reassessed 
individually and reclassified according to ACMG criteria, following co-segregation analysis, 
literature- and database- review.24-28 RBM20-variants identified within the Arginine-Serine 
rich domain of exon 9 were considered to fulfil the hotspot ACMG-criteria (PM1) since 
previous investigations have reported identical pathogenic variants in the same domain and 
no benign variants have been reported so far. Evidence of segregation was considered as 
strong when appearing in ≥7 affected individuals, moderate when appearing in ≥5 and 
supporting when appearing in ≥3.29   
 
Variants classified as pathogenic according to ACMG were considered to be disease 
associated and suitable for genetic testing when they: 
(a) Appeared in ≥ seven individuals fulfilling DCM diagnostic criteria based on the 
findings in the current study and previous reports.24-27, 30 
(b) Occurred with an allele frequency < 1:10.000 in the Genome Aggregation Database 
(gnomAD).28, 31 
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Haplotype Analysis 
To investigate if common founders of families carrying identical pathogenic RBM20-variants 
were present, haplotype analyses were made by the use of Sanger sequencing of three single 
nucleotide polymorphisms (SNP) in the three-prime-untranslated-region (3-UTR) of RBM20 
(genomic positions: 112596184/c.*448C>T; 112596570/c.*834G>T and 
112598602/c.*2866C>T). All SNPs were localized within a distance of less than 27.000 
nucleotides from the pathogenic RBM20-variant. On average three carriers of the pathogenic 
variant and one non-carrier from each family were selected for haplotype analysis. The 
primers used for haplotype analysis are available upon request. 
 
Statistics 
Continuous variables were reported as mean ± standard deviation (SD) for normally 
distributed data or otherwise as median and interquartile range (IQR). Categorical variables 
were reported as numbers and percentages. Comparisons of groups were made by use of 
students T-test or the Mann-Whitney test for continuous variables where appropriate and χ2- 
or Fishers exact-test were used where appropriate for categorical variables. Comparisons of 
more than two groups with normally distributed data were made by the use of one-way 
ANOVA test and the Bonferroni test for pairwise comparison. Comparisons of more than two 
groups with non-parametric data were made by the use of Kruskal Wallis test and Dunn’s test 
for pairwise comparison (Bonferroni). The follow-up period in survival analyses lasted from 
the date of birth until the first episode of VA, HTx, death from HF (composite endpoint) or 
the date of the most recent follow-up (censoring). Event rates were estimated using the 
Kaplan-Meier method and compared using the log-rank test. Furthermore, univariate cox 
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proportional hazard regression was used to calculate hazard ratios (HR) and 95% confidence 
intervals (CI). Family structure was taken into account by estimating robust clustered 
standard errors. P-values <0.05 were considered to be statistically significant. Statistical 
analyses were performed by the use of software from STATA (version 15). 
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Results 
 
Genetic Investigations 
Initially clinical and genetic investigations of ≥76 potential DCM related genes were 
performed in 111 DCM-index patients including 436 of their relatives at risk of having 
inherited the condition.32 Familial DCM occurred in 34% (38/111) of cases. A total of 14 
different pathogenic DNA-sequence-variants suitable for genetic testing were identified in 19 
apparently unrelated index-patients (17%) with a frequency of 45% (17/38) in familial DCM 
and 3% (2/73) in sporadic DCM. The frequency of pathogenic RBM20-variants in this cohort 
of patients was 6% (7/111) and appeared in familial DCM only. Following these results, 
genetic investigations were routinely offered to all consecutive index-patients with familial 
DCM and an additional eight RBM20 families were identified and included in this study.  
 
The genetic investigations identified five different recognized pathogenic RBM20-variants 
suitable for genetic testing in 15 families with a total of 80 carriers (Figure 1 and Table 1: 
p.Arg634Gln, p.Arg636His, p.Arg636Ser, p.Pro638Leu and p.Glu913Lys).6, 8-12  
Ten index-patients were shown to carry the same p.Arg636Ser amino acid substitution. Seven 
of these families were available for haplotype analyses which revealed co-segregation 
between three intra-genic SNPs of RBM20 and p.Arg636Ser. These findings suggested a 
common disease allele and thereby a common founder of the pathogenic variant.  
 
In family B the index-patient and one affected relative carried the recognized disease-
associated pathogenic RBM20-variant p.Arg636Ser as well as a VUS within the DCM gene 
for BAG3 (p.Arg71Trp) which appeared with a frequency of 1:7070 in gnomAD (Table 1).33 
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An additional four index-patients were shown to carry four different VUS of RBM20 (Table 
1: p.Met196Val, p.Arg392Trp, p.Asp674Gly and p.Pro1039Ser). Three of these index-
patients also carried a pathogenic truncating TTN variant or a VUS in recognized DCM genes 
for either ACTC1 or TNNI3 (Table 1 and Figure 1S).34-36 Unfortunately, the number of 
affected individuals in these families was too small to draw conclusions about the potential 
pathogenicity of these sequence variants and therefore they were excluded from the analyses 
in this study.   
 
Clinical Investigations of RBM20-carriers 
Age at Diagnosis and Symptoms 
Clinical investigations of 80 individuals carrying pathogenic RBM20-variants within 15 
families identified a total of 53 affected individuals including index-patients, which resulted 
in a penetrance of 66% (53/80). They were followed for a median period of 86 months (24 – 
150 months) from their first clinical evaluation and were diagnosed with DCM at their initial 
investigation (n=49) or developed the condition during follow-up (n=4). The mean age at 
diagnosis of index-patients and affected relatives was 40 ± 15 and 35 ± 15 years respectively. 
Most affected individuals were diagnosed between 30 and 39 years of age (Figure 2 and 
Table 2). Twenty-seven individuals (34%) had a normal phenotype at their most recent 
follow-up at a mean age of 38 ± 17 years (males: 37 ± 17 years; females: 40 ± 17 years) 
(Figure 1, 3 and Table 2). 
 
The total number of relatives carrying pathogenic RBM20-variants without symptoms of 
cardiac disease was 44 of which 17 (39%) were diagnosed with DCM following clinical 
family screening (Figure 3). These asymptomatic individuals with DCM were identified at a 
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significantly younger age compared to 16 symptomatic relatives who were diagnosed with 
DCM because of cardiac symptoms before family screening was initiated (29 ± 12 vs. 43 ± 
16 years, p=0.02) (Table 2S).  
 
An additional five relatives who were obligate carriers of pathogenic RBM20-variants died 
suddenly as the initial symptom of disease at an average age of 35 ± 6 (Figure 1: Family D: 
III.4 and III.6. Family F: II.2 and II.3. Family H: II.1). They all underwent autopsy and 
received a post-mortem diagnosis of DCM. According to the autopsy report of individual 
FII.3 her heart was enlarged with a dilated LV and a weight of 475 g (0.8% of her body 
weight). The histology was characterized by myocyte hypertrophy and fibrosis. 
Unfortunately details of the autopsies in the remaining four SCDs were unavailable except 
for the main conclusion.  
 
Echocardiography 
Echocardiography of all carriers of pathogenic RBM20-variants with DCM at initial diagnosis 
revealed a mean LVEDd and LVEF of 65 ± 9 mm and 32 ± 12 %, respectively (Table 3). 
Asymptomatic individuals who fulfilled DCM diagnostic criteria and identified by clinical 
investigations of relatives had a significantly better LVEF than relatives who had been 
referred due to symptoms (LVEF: 38 ± 8 vs. 27 ± 12 %, p=0.03) (Table 2S). There was no 
significant change in LVEF (32 ± 12 vs. 32 ± 13%; p=0.76) or LVEDd (66 ± 10 vs. 68 ± 
10mm; p=0.11) of RBM20-carriers with DCM after an average period of seven years of 
follow-up. 
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Arrhythmias 
Two individuals had supraventricular arrhythmias at diagnosis, while ten developed atrial 
fibrillation during follow-up. One individual developed a sick sinus node syndrome at the age 
of 51. Five individuals developed left bundle branch block (LBBB). No one was diagnosed 
with advanced atrioventricular conduction disease.  
Three individuals were successfully resuscitated from a cardiac arrest due to VF while two 
individuals had episodes of sustained VT requiring cardioversion. Five of 16 patients treated 
with a primary prophylactic ICD received appropriate shock at a mean age of 40 ± 6 years 
and a median follow-up period of five years. Two of these individuals underwent HTx at a 
later stage. One individual who had been followed for eight years with a LVEF of 30%, died 
suddenly at the age of 33. An additional, five individuals also died from SCD as mentioned 
above. Most affected individuals experienced their first episode of VA between 30 and 39 
years of age (Figure 2).  
 
In total, 16 of the 53 individuals with DCM (30%) experienced at least one episode of severe 
VA. There was no significant difference in LVEF at diagnosis among patients with episodes 
of VAs compared with DCM patients without VAs (28 ± 13 vs. 34 ± 12 %; p=0.19), while 
the mean LVEF preceding an episode of sustained VT or VF was 30 ± 12 % (median 30%, 
range: 10 – 47%). However, 36% (4/11) of the patients with DCM who experienced a VA 
had a LVEF > 30%. There was no difference in HF therapy with ACE-inhibitors and beta-
blockers between patients with and without VAs (p=0.69 and p=0.13, respectively).  
RBM20-carriers with a normal echocardiography did not have symptoms or documented 
episodes of VAs by Holter-recordings. 
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Sex Specific Disease Expression 
Eleven males from eight different families and no females underwent HTx due to end-stage 
HF (p<0.01) at a mean age of 33 ± 16 years (Table 3). Four teenagers from three different 
families received a transplant at the age of 13 (II.2, family R), 14 (III.2, family G), 17 (III.5, 
family H) and 18 (III.7, family H) (Figure 1).   
Males were diagnosed at a significantly younger age than females (29 ± 11 vs. 48 ± 12 years, 
p<0.001). They also had a lower LVEF at diagnosis (29 ± 13 % vs. 38 ± 8 %, p<0.009), while 
the difference in LVEDd at diagnosis was non-significant when indexed for BSA (Table 3). 
Males were significantly younger when experiencing their first episode of VA (37 ± 5 vs. 54 
± 16 years, p=0.006). By the age of 40 years 60% males had either received a cardiac 
transplant or experienced VA while this happened in less than 5% of females (Figure 4A). 
However, there was no significant sex specific difference in the number of VA episodes 
(Table 3). Affected males also died or experienced a disease complication significantly 
earlier in life than affected females (log-rank; p<0.001. HR 24.05; 95% CI, 2.98 – 196.21; 
p=0.003) (Figure 4A). There were no significant differences in the number individuals who 
were identified by family screening, their NYHA class, pharmacological HF treatment, or the 
frequency of ICD implantations between sexes (Table 3). Adjusting for family structure did 
not change the significance levels in the statistical analyses (data not shown). 
 
Disease Expression Among Affected Relatives 
Affected relatives who were asymptomatic at diagnosis were diagnosed with DCM at a 
younger age, had a higher LVEF at diagnosis (38 ± 8% vs. 27 ± 12; p=0.03), and fewer 
episodes of VAs during follow-up (6 vs. 52%; p=0.008) than affected relatives who were 
symptomatic at diagnosis (Table 2S). Two of the asymptomatic relatives at diagnosis 
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deteriorated rapidly during follow-up and underwent HTx at the age of 17 and 19 years 
respectively (Table 2S). There were no significant differences between index-patients and 
their affected relatives regarding pharmacological HF treatment, frequency of ICD 
implantations, VAs and HTx during follow-up (Table 2S).”  
 
Comparison of the Disease Expression Among DCM Patients Carrying Pathogenic RBM20 
and Patients Having Familial DCM of Unknown Genetic Etiology  
The disease expression among carriers of pathogenic RBM20-variants and patients with 
familial disease in whom the genetic investigations failed to identify any pathogenic or likely 
pathogenic variants was compared. 
Male patients (n=31) with DCM carrying pathogenic RBM20-variants were significantly 
younger at diagnosis (29 ± 11 vs. 49 ± 16 years, p<0.001) than males (n=30) with familial 
DCM of unknown genetic etiology (Table 4). In addition, they had a significantly shorter 
event-free survival than males with familial DCM of unknown genetic etiology (log-rank; 
p=0.001. HR 3.47; 95% CI, 1.58 – 7.60; p=0.002) (Figure 4B). There were no further 
differences in the clinical characteristic, pharmacological HF treatment or frequency of ICD 
implantations between males in the two groups.   
Female patients (n=22) with DCM carrying pathogenic RBM20-variants were significantly 
older at diagnosis than females (n=14) with familial DCM of unknown genetic etiology (48 ± 
12 vs. 33 ± 16 years, p=0.003). There were no further significant differences in clinical 
characteristics, pharmacological HF treatment, frequency of ICD implantations or event-free 
survival between females in the two groups (log-rank; p=0.19. HR 0.46; 95% CI, 0.14 – 1.51; 
p=0.20) (Supplementary material: Table 3S and Figure 2S).    
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Discussion 
 
Genetic Investigations and Penetrance 
Five recognized pathogenic RBM20-variants were identified of which the p.Arg636Ser amino 
acid substitution appeared in more than two thirds of all RBM20-carriers.6, 8-12 Haplotype 
analyses using three SNPs localized in close proximity to the pathogenic RBM20-variant 
suggested that this variant was likely to have originated from a common founder.  
 
A number of rare sequence variants were identified in RBM20 as well as in additional 
recognized DCM genes. Although they were absent in controls the number of affected 
carriers of these variants were too small to determine their possible impact on disease 
expression and therefor, they were considered unsuitable for genetic testing. Future studies 
may help to determine the impact of these variants and also clarify if DCM in the context of 
RBM20-disease may be explained by di-genic inheritance due to the appearance of variants in 
more than one recognized DCM gene as seen in four index patients of this study (Table 1 and 
Figure 1S).  
 
The penetrance of DCM among carriers of pathogenic RBM20-variants was 66% including 
index-patients and depended on age and sex with males being diagnosed at a significantly 
younger age than females. Remarkably, seven young males and no females developed DCM 
in their teens necessitating HTx in four individuals before the age of 19.  
 
Clinical Investigations and Disease Expression 
The disease expression was severe since one third of affected carriers died suddenly or 
experienced at least one episode of VF/sustained VT during seven years of follow-up. In 
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addition, 21% received a cardiac transplant. Again, the disease expression was significantly 
worse among males in whom 60% experienced a major cardiac event before the age of 40 
years while this occurred in less than 5% of females (Figure 4A).  
 
It was evident that male DCM patients carrying pathogenic RBM20-variants had a 
significantly shorter event-free survival than males with familial DCM of unknown genetic 
etiology (Figure 4B). Furthermore, female RBM20-carriers were older at diagnosis than both 
females with familial DCM of unknown genetic etiology and male RBM20-carriers.  
This sex specific disease expression may be explained by yet unidentified modifying genetic 
variants, which may protect female carriers from adverse events in addition to differences in 
lifestyle, hormonal status and overall genetic constitution. In this context, it is of interest that 
a similar sex specific disease expression has been reported to be associated with pathogenic 
variants in the gene for lamin A/C, in which males appeared to have more episodes of 
malignant VAs and a higher frequency of end-stage HF than females.37  
 
The fact that males had a lower LVEF at diagnosis than females may well explain the high 
frequency of HTx and SCD among male RBM20-carriers. Furthermore, the absence of VA 
and symptoms of disease in RBM20-carriers with a normal cardiac investigation also 
suggested that VA were related to impaired LV function. However, VAs also appeared in 
four individuals with a LVEF between 30-47%, suggesting that other factors than impaired 
LV function may be associated with VAs. Interestingly, the results of a recent investigation 
of a RBM20 knock-out mouse model showed that loss of the protein for RBM20 disturbed 
Ca2+ handling and lead to a more pro-arrhythmic Ca2+ release from the sarcoplasmic 
reticulum which may explain the high frequency of VAs.38 In order to substantiate these 
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findings, additional experimental studies of genetically modified animal models expressing 
pathogenic missense variants identified in humans would be required to provide a basis for 
future pharmacological intervention studies. 
 
Clinical implications 
Based on the findings in this and previous studies pathogenic variants within RBM20 
appeared to be associated with an adverse prognosis in both index-patients and their relatives. 
The finding of DCM in 39% of otherwise asymptomatic RBM20-carriers illustrated the 
importance of family screening. These individuals were identified 14 years earlier than 
relatives who had been diagnosed with DCM due to symptoms of HF. The diagnosis of 
asymptomatic individuals with DCM allowed initiation of pre-symptomatic anti-congestive 
medical therapy which may hopefully postpone the development of severe LV dysfunction, 
VA and the need for HTx. 
Close clinical surveillance of RBM20-carriers from the age of 10 appeared important since 
several individuals developed end-stage HF in their teens while few carriers experienced 
adverse complications beyond the age of 70 years.    
 
Limitations 
The study was conducted at three tertiary referral University Hospitals of which one was also 
a transplant center which may have introduce referral bias towards more severely affected 
individuals.  
Haplotype analyses suggested that the most frequent pathogenic RBM20-variant 
(p.Arg636Ser) in the cohort was likely to have arisen from a common ancestor. This may 
have represented a potential confounder towards a more uniform disease expression among 
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carriers due to a common genetic background. However, the disease expression associated 
with the p.Arg636Ser variant observed in this study appeared to be the same as reported 
previously which favored an effect of the pathogenic RBM20-variant by itself more than a 
potential effect of common ancestry.8  
The fact that males with familial DCM of unknown genetic etiology were significantly older 
at diagnosis compared males with DCM carrying pathogenic RBM20-variants may have 
introduced a confounder because the development of their condition may have been 
influenced by a longer exposure to environmental and lifestyle risk for developing DCM.  
 
Conclusion 
Pathogenic RBM20-variants appeared to be associated with a severe disease expression and 
an early onset especially in males. These findings suggested that clinical and genetic 
investigations are important to identify patients at high risk of developing disease 
complications in order to initiate adequate and timely treatment.  
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Figure 1 Pedigrees of 15 DCM families carrying pathogenic RBM20-variants.  
Square = male; circle = female; arrow = index-patient; slash = deceased individual; open 
symbol = unaffected individual; solid symbol = individual with DCM; plus sign upper right = 
presence of pathogenic RBM20-variant; minus sign upper right = absence of pathogenic 
RBM20-variant; circle upper left = BAG3 VUS; minus sign upper left = absence of BAG3 
VUS. No clinical data were available in nine obligate RBM20-carriers (family D: II.1, II.5, 
II.6; family E: II.1, II.2, II.3, III.8, III.13; family V: II.3) or in individual II.1 from family B. 
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Figure 2  
Age distribution among affected carriers of pathogenic RBM20-variants at diagnosis in black 
bars. Grey bars show the age of affected carriers at first episode of ventricular fibrillation, 
sustained ventricular tachycardia or sudden cardiac death. VF = ventricular fibrillation; VT = 
ventricular tachycardia. 
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Figure 3  
Distribution of carriers of pathogenic RBM20-variants identified due to symptoms or by 
clinical family screening. An additional four index-patients were shown to carry VUS within 
RBM20 and did not take part in any of the analyses in the study. 
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Figure 4  
Panel A Event-free survival of males and females with DCM carrying pathogenic RBM20-
variants. Events were defined as death from end-stage heart failure, cardiac transplantation, 
sudden cardiac death and first episode of ventricular fibrillation or sustained ventricular 
tachycardia. Hatch-mark indicates age at most recent follow-up. 
Panel B Event-free survival of males with DCM carrying pathogenic RBM20-variants and 
males with familial DCM of unknown genetic etiology. Events were defined as death from 
end-stage heart failure, cardiac transplantation, sudden cardiac death and first episode of 
ventricular fibrillation or sustained ventricular tachycardia. Hatch-mark indicates age at most 
recent follow-up. 
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Tables 
Table 1 Affected Families With DNA-Sequence Variants in RBM20 and Additional Recognized DCM Genes. 
Gene Predicted amino acid change Genomic 
position 
Family Number of affected carriers: 
current study/previous studies 
AF in 
gnomAD  
ACMG criteria ACMG variant 
classification 
RBM20 p.Arg634Gln/c.1901G>A 112572056 A 2/108,10 - PS4:PM1;PM2;PP1;PP3 P     
RBM20 p.Arg636His/c.1907G>A 112572062 G, U 4/126,8,9,10 - PS4:PM1;PM2;PP1;PP3 P 
RBM20 p.Arg636Ser/c.1906C>A 112572061 B†, C, D, E, F, 
Q, S, T, V, W  
38/98 - PS4:PM1;PM2;PP1;PP3 P  
RBM20 p.Pro638Leu/c.1913C>T 112572068 R 1/178,11 - PS4:PM1;PM2;PP1;PP3 P     
RBM20 p.Glu913Lys/c.2737G>A 112581114 H 8/012 - PS3;PS4:PM2;PP1;PP3 P 
RBM20 p.Met196Val/c.586A>G 112540953 J 2/0 - PM2;BP4 VUS 
ACTC1 p.Ala333Val/c.998C>T 35082749 J 3/0 - PM2;PP2;PP3 VUS 
RBM20 p.Arg392Trp/c.1174C>T 112541541 K 1/0 2/154530 PM2 VUS 
TNNI3 p.Lys178Arg/c.530A>G 55665414 K 1/0 - PM2;PP3 VUS 
RBM20 p.Asp674Gly/c.2021A>G 112572176 M 2/0 3/186480 PM2 VUS 
RBM20 p.Pro1039Ser/c.3115C>T 112581492 I 3/0 40/188260 - VUS 
TTN p.Leu20218Tyrfs*118/c.60653delT 179422144 I 2/0 - PVS1;PM2;PM4 P 
BAG3 p.Arg71Trp/c.211C>T 121429393 B† 2/0 40/282786 - VUS 
 
 
 
 
37 
†Affected individuals in family B also carried a rare sequence variant in a different recognized DCM gene (BAG3: p.Arg71Trp). ACMG = 
American College of Medical Genetics and Genomics and the Association for Molecular Pathology. AF = allele frequency; gnomAD = 
genome aggregation database (http://gnomad.broadinstitute.org); P = pathogenic; VUS = variant of unknown significance.  
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Table 2 Penetrance, Age Distribution and Duration of Follow-up of Individuals Carrying Pathogenic RBM20-variants 
 
*Follow-up data was available in 48 individuals since five individuals had died suddenly as the initial manifestation of disease. DCM = 
dilated cardiomyopathy; IQR = interquartile range (25-75%); n = number; SCD = sudden cardiac death; SD = standard deviation.  
 
 
 
Pathogenic 
RBM20- 
variant 
Families/ 
number of 
RBM20- 
carriers 
Penetrance: 
Individuals with 
DCM/All 
RBM20-carriers 
(%) 
Age at diagnosis 
of index-
patients 
±SD (n) 
Age at diagnosis of 
asymptomatic relatives 
with DCM identified by 
cascade screening 
±SD (n) 
Age at diagnosis 
of symptomatic 
relatives with 
DCM 
±SD (n) 
Age of individuals 
who experienced 
SCD as initial 
symptom of disease  
±SD (n) 
Age at most recent 
follow-up of healthy 
individuals  
±SD (n) 
Age at diagnosis of 
individuals who 
developed DCM at 
follow-up 
±SD (n) 
Median duration of 
follow-up in months 
of individuals with 
DCM* 
(IQR); (n) 
p.Arg634Gln 1/8 2/8 (25) 37 (1) - 42 (1) - 35 ± 16 (6) - 135, 156 (2) 
p.Arg636His 2/6 4/6 (67) 27; 46 (2) 44 (1) 14 (1) - 22; 28 (2) - 83 (25 – 162); (4) 
p.Arg636Ser 10/56 38/56 (68) 45 ± 14 (10) 20 ± 12 (11)  43 ± 14 (13) 37 ± 5 (4) 41 ± 18 (18) 43 (1) 99 (25 – 161); (34) 
p.Pro638Leu 1/1 1/1 (100) 13  (1) - - - - - 0; (1) 
p.Glu913Lys 1/9 8/9 (88) 36 (1) 24 ± 12 (5) 71 (1) 28 (1) 28 (1) 27 ± 15 (3) 37 (11 – 121); (7) 
Total 15/80 53/80 (66) 40 ± 15 (15) 29 ± 12 (17) 43 ± 16 (16) 35 ± 6 (5) 38 ± 17 (27) 31 ± 15 (4) 86 (24 – 150); (48) 
Table 3 Sex Related Disease Expression and Treatment of DCM Patients Carrying 
Pathogenic RBM20-variants 
Variables Total Male Female p 
Number of carriers with DCM (%) 53 (100) 31 (58) 22 (42) 0.70 
Number of index-patients (%) 15/53 (28) 8/31 (26) 7/22 (32) 0.63 
Mean age at diagnosis in years ± SD 37 ± 15 29 ± 11 48 ± 12 <0.001 
Number of individuals with NYHA class ≥II at diagnosis (%)* 26/48 (54) 15/28 (54) 11/20 (55) 0.92 
Number of asymptomatic DCM patients identified by family screening (%) 17/53 (32) 12/31 (39) 5/22 (23) 0.22 
Age at diagnosis in years of DCM relatives identified by family screening ±SD 29 ± 12 26 ± 12 35 ± 9 0.20 
     
Mean LVEDd in mm at diagnosis ± SD† 65 ± 9 68 ± 9 60 ± 5 <0.001 
Mean LVEDd/BSA in mm/m2 (IQR) † 33 (31 – 37) 35 (31 – 38) 32 (31 – 34) 0.21 
Mean LVEF in % at diagnosis  ± SD† 32 ± 12 29 ± 13 38 ± 9 0.009 
     
Number of individuals treated with an ACE-I or AT-II receptor blocker (%)* 42/48 (88) 24/28 (86) 18/20 (90) 0.69 
Number of individuals treated with a beta-blocker (%)* 35/48 (73) 18/28 (64) 17/20 (85) 0.11 
Number of individuals who had an ICD implanted (%)* 21/48 (44) 11/28 (39) 10/20 (50) 0.46 
     
Number of individuals who underwent HTx (%) 
Mean age at HTx in years ± SD 
11/53 (21) 
33 ± 16 
11/31 (34) 
33 ± 16 
- 
- 
0.002 
- 
Number of individuals who died from end-stage HF (%) 2/53 (4) - 2/22 (9) 0.17 
Age at death in years 54; 73 - 54; 73 - 
Number of individuals who experienced SCD, VF or sustained VT (%) 
Mean age at first event of SCD, VF or sustained VT ±SD 
16/53 (30) 
44 ± 14 
9/31 (29) 
36 ± 5 
7/22 (32) 
54 ± 16 
1.00 
0.006 
* Information on NYHA class, medical treatment and ICD implantation was available in 48 
individuals. † Echocardiography was available in 46 individuals. ACE-I= angiotensin 
converting enzyme inhibitor; AT-II= angiotensin-II; DCM= dilated cardiomyopathy; HTx= 
heart transplantation; ICD = implantable cardioverter defibrillator; IQR = interquartile range 
(25-75%); LVEDd= left ventricular end-diastolic diameter; LVEF= left ventricular ejection 
fraction; SCD= sudden cardiac death; SD= standard deviation; VF= ventricular fibrillation; 
VT= ventricular tachycardia. 
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Table 4 Male Patients With Familial DCM Carrying Pathogenic RBM20-variants or variants 
of Unknown Genetic Etiology 
 Total RBM20 carriers Unknown etiology p 
Number with male sex (%) 61/61 (100) 31/61 (51) 30/61 (49) - 
Number of index-patients (%) 22/61 (36) 8/31 (26) 14/30 (47) 0.10 
Mean age in years at diagnosis ± SD 39 ± 17 29 ± 11 49 ± 16 <0.001 
NYHA class ≥ II at diagnosis (%)* 31/52 (60) 15/28 (54) 16/24 (67) 0.34 
Number of DCM patients identified due to clinical family investigation (%) 17/61 (28) 12/31 (39) 5/30 (17) 0.06 
     
Mean LVEDd at diagnosis in mm ± SD† 68 ± 10 68 ± 9 67 ± 11 0.81 
Median LVEDd/BSA at diagnosis in mm/BSA (IQR) † 33 (30 – 38) 35 (31 – 38) 32 (30 – 39) 0.69 
Mean LVEF at diagnosis in % ± SD† 27 ± 12 29 ± 13 28 ± 12 0.35 
     
Number of individuals treated with ACE-I or AT-II receptor blocker (%)* 42/52 (81) 24/28 (88) 18/24 (78) 0.33 
Number of individuals treated with a beta-blocker (%)* 31/52 (60) 18/28 (64) 13/24 (54) 0.45 
Number of individuals who had an ICD implanted (%)* 15/52 (29) 11/28 (39) 4/24 (17) 0.07 
     
Number of individuals who received a cardiac transplant (%) 18/61 (30) 11/31 (35) 7/30 (23) 0.30 
Mean age in years at HTx ±SD 38 ± 16 33 ± 16 46 ± 13 0.74 
Number of individuals who experienced SCD, VF or sustained VT (%) 17/61 (28) 9/31 (29) 8/27 (30) 0.84 
Mean age in years at SCD, VF or sustained VT ± SD 37 ± 12 36 ± 5 38 ± 18 0.70 
Median duration of follow-up in months (IQR) 40 (0 – 98) 48 (4 – 100) 23 (0 – 73) 0.14 
 
*Information about NYHA class, medical treatment was available in 52 individuals.  
†Echocardiography at diagnosis was available in 50 individuals. ACE-I = angiotensin 
converting enzyme inhibitor; AT-II = angiotensin-II; HTx = heart transplantation; ICD = 
implantable cardioverter defibrillator; IQR = interquartile range (25-75%); LVEDd = Left 
ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; NYHA= New 
York Heart Association; SCD = sudden cardiac death; SD = standard deviation; VF = 
ventricular fibrillation; VT = ventricular tachycardia. 
Supplemental Material 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1S Pedigrees of 4 DCM families carrying DNA-sequence variants of unknown significance 
(VUS) in RBM20 and sequence variants in additional recognized DCM genes.  
Family I: Individual II.1 and II.2 had DCM and carried a VUS in both RBM20 and TTN. Individual 
II.4, III.5 and III.6 had a normal cardiac investigation at the age of 48, 22 and 23 respectively. They 
were shown to carry the same VUS in RBM20 and TTN as their affected relatives. Individual I.2 
was diagnosed with DCM at the age of 73 and carried the RBM20 VUS in isolation. She had also 
hypertension, type II diabetes and chronic obstructive pulmonary disease which may have explained 
her cardiac condition.  
Family J: Individual I.2 and II.1 had DCM and carried a VUS in both RBM20 and ACTC1. 
Individual II.2 also had DCM and carried the ACTC1 VUS while she did not consent to be tested 
for the VUS in RBM20.   
+
Family I (RBM20: p.Pro1039Ser(+); TTN: p.Leu20218Tyrfs*118(o)) 
Family J (RBM20: p.Met196Val(+); ACTC1:p.Ala333Val(o)) 
Family K (RBM20: p.Arg392Trp(+); TNNI3: p.Lys178Arg(o)) Family M (RBM20: p.Asp674Gly(+))  
+	
_	
	
+	 +	 +	
Family K: Individual II.1 had DCM and carried a VUS in RBM20 as well as a VUS in TNNI3. 
Individual II.3 and II.4 carried the RBM20 in isolation and had a normal cardiac investigation at the 
ages of 64 and 67 years, respectively. 
Family M: Individual II.2 and II.4 had DCM and carried a VUS in RBM20. Individual II.3, III.1, 
III.2, and III.3 also carried the RBM20 VUS but had a normal cardiac investigation at the age of 71, 
41, 47 and 49 years, respectively. 
Square = male; circle = female; arrow = index-patient; Slash = deceased individual; open symbol = 
unaffected individual; solid symbol = individual with DCM; plus sign upper right = presence of 
RBM20 VUS; minus sign upper right = absence of RBM20 VUS; circle upper left = VUS in 
additional DCM genes; minus sign upper left = absence of VUS in additional DCM genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2S Event-free survival of female carriers of pathogenic RBM20-variants with DCM and 
females with familial DCM of unknown genetic aetiology. Events were defined as death from end-
stage heart failure, cardiac transplantation, sudden cardiac death and first episode of ventricular 
fibrillation or sustained ventricular tachycardia. Hatch-mark indicates age at most recent follow-up. 
 
 
 
 
 
 
 
Table 1S 76 Recognized and Likely DCM Genes Investigated in all Index-patients 
Genes 
ABCC9, ACTC1, ACTN2, ADRB1, ADRB2, ADRB3, ANKRD1 
BAG3 
CACNA1C, CACNB2, CALR3, CASQ2, CAV3, CBFB, CRYAB, CSRP3, CTF1 
DES, DMD, DSC2, DSG2, DSP 
EYA4 
GPD1L 
ILK 
JPH2, JUNB, JUP 
KCNE1, KCNE2, KCNH2, KCNJ2, KCNJ8, KCNQ1, KCNQ2 
LAMP2, LDB3, LIMS1, LIMS2, LMNA 
MYBPC3, MYH6, MYH7, MYL2, MYL3, MYOZ2, MYPN 
NEXN 
PARVB, PDLIM3, PKP2, PLN, PRKAG2, PSEN1, PSEN2 
RBFOX1, RBM20, RYR2 
SCN1B, SCN4B, SCN5A, SGCD, SMYD1, SMYD2, SNTA1 
TAZ, TBX20, TCAP, TGFB3, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TTN 
VCL 
 
 
 
 
 
 
Table 2S Clinical characteristics of Index-patients Carrying pathogenic RBM20-variants and their 
affected relatives at diagnosis and during follow-up.  
 
*Statisical significant difference between groups (a = Index-patients, b = Affected relatives who were 
symptomatic at diagnosis and c =  Affected relatives who were asymptomatic at diagnosis). 
†Echocardiography was available in 46 individuals. ‡Five relatives who died suddenly as initial 
manifestation of disease were not included. ACE-I= angiotensin converting enzyme inhibitor; AT-
Variables Total Index-patientsa 
Affected relatives who 
were symptomatic at 
diagnosisb 
Affected relatives who 
were Asymptomatic at 
diagnosisc 
p 
At diagnosis      
Number of affected RBM20 carriers with DCM (%) 53 (100) 15/53 (28) 21/53 (39) 17/53 (32) - 
Mean age at diagnosis ± SD 37 ± 15 40 ± 15 43 ± 16*c 29 ± 12*b 0.02 
Number of males with DCM (%) 31/53 (58) 8/15 (53) 11/21 (52) 12/17 (71) 0.47 
      
Mean LVEDd in mm at diagnosis ± SD†‡ 65 ± 9 64 ± 9 68 ± 11 62 ± 5 0.12 
Mean LVEDd/BSA at diagnosis  in mm/m2 (IQR)†‡ 33 (31 – 37) 32 (31 – 36) 36 (32 – 39) 32 (31 – 35) 0.10 
Mean LVEF in % at diagnosis  ± SD†‡ 32 ± 12 32 ± 13 27 ± 12*C 38 ± 8*b 0.03 
 
At follow-up 
 
 
   
Number of individuals treated with an ACE-I/AT-II (%)‡ 42/48 (88) 14/15 (93) 14/16 (88) 14/17 (82) 0.65 
Number of individuals treated with a beta-blocker (%)‡ 35/48 (73) 13/15 (87) 12/16 (75) 10/17 (59) 0.20 
Number of individuals who had an ICD implanted (%)‡ 21/48 (44) 6/15 (40) 9/16 (38) 6/17 (35) 0.45 
      
Number of individuals who underwent HTx (%) 11/53 (21) 5/15 (33) 4/21 (19) 2/17 (12) 0.31 
Mean age at HTx ± SD 33 ± 16 39 ± 17 32 ± 15 17; 19 0.30 
Number of individuals who died from end-stage HF (%) 2/53 (4) - 2/16 (13) - - 
Mean age of death ± SD 54; 73  54; 73 - - 
Number of individuals who experienced a VA (%)  16/53 (30) 4/15 (27) 11/21 (52)*c 1/17 (6)*b 0.008 
Mean age at first event of VA ±SD 44 ± 14 45 ± 5 44 ± 17 35 0.84 
Median duration of follow-up in months (IQR) 86 (24 – 150) 117 (18 – 163) 99 (40 – 195) 48 (11 – 127) 0.32 
II= angiotensin-II; DCM= dilated cardiomyopathy; HTx= heart transplantation; ICD = implantable 
cardioverter defibrillator; IQR = interquartile range (25-75%); LVEDd= left ventricular end-
diastolic diameter; LVEF= left ventricular ejection fraction; SD= standard deviation; VA= 
ventricular arrhythmia (including ventricular fibrillation, sustained ventricular tachycardia and 
sudden cardiac death). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3S Female Patients with Familial DCM Caused by Pathogenic RBM20-variants or of 
Unknown Genetic Etiology 
 Total RBM20 carrier Unknown etiology p 
Number with female sex (%) 36/36 (100) 22/36 (51) 14/36 (49) - 
Number of index-patients (%) 14/36 (39) 7/22 (32) 7/14 (50) 0.28 
Mean age in years at diagnosis ± SD 42 ± 15 48 ± 12 33 ± 16 0.003 
NYHA class ≥II at diagnosis (%)* 18/33 (55) 11/20 (55) 6/13 (46) 0.62 
Number of DCM patients identified due to clinical family investigation (%) 9/36 (25) 5/22 (23) 4/14 (29) 0.69 
     
Mean LVEDd at diagnosis in mm ± SD† 60 ± 6 60 ± 5 61 ± 8 0.51 
Median LVEDd/BSA at diagnosis in mm/m2 (IQR)† 33 (31 – 36) 32 (31 – 34) 36 (30 – 39) 0.12 
Mean LVEF at diagnosis in % ± SD† 36 ± 10 38 ± 9 32 ± 11 0.11 
     
Number of individuals treated with a ACE-I or AT-II receptor blocker (%)* 29/33 (83) 18/20 (90) 11/13 (85) 0.64 
Number of individuals treated with a beta-blocker (%)* 25/33 (76) 17/20 (85) 8/13 (62) 0.12 
Number of individuals who had an ICD implanted (%)* 13/33 (39) 10/20 (50) 3/13 (23) 0.12 
     
Number of individuals who received a cardiac transplant (%) 3/36 (8) - 3/14 (21) 0.05 
Age in years at HTx 12; 37; 42 - 12; 37; 42 - 
Number of individuals who experienced SCD, VF or sustained VT (%) 9/36 (25) 7/22 (32) 2/14 (14) 0.43 
Mean age in years at SCD, VF or sustained VT ± SD 52 ± 16 54 ± 16 32; 58 - 
Median duration of follow-up in months (IQR) 116 (48 – 186) 135 (55 – 191) 69 (43 – 115) 0.12 
 
*Information about NYHA class, medical treatment and ICD implantation was available in 33 
individuals. †Echocardiography at diagnosis was available in 33 individuals. ACE-I = angiotensin 
converting enzyme inhibitor; AT-II = angiotensin-II; HTx = heart transplantation; ICD = 
implantable cardioverter defibrillator; IQR = interquartile range (25-75%); LVEDd = Left 
ventricular end-diastolic diameter; LVEF = left ventricular ejection fraction; NYHA = New York 
Heart Association; SCD = sudden cardiac death; SD = standard deviation; VF = ventricular 
fibrillation; VT = ventricular tachycardia.  
